<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01157728</url>
  </required_header>
  <id_info>
    <org_study_id>P071102</org_study_id>
    <nct_id>NCT01157728</nct_id>
  </id_info>
  <brief_title>Early Cognitive Impairment in Multiple Sclerosis</brief_title>
  <acronym>CogniSEP</acronym>
  <official_title>Early Cognitive Impairment in Multiple Sclerosis: a Multimodal MRI Study Evaluating the Relative Contribution of Cortical and White Matter Tract Injury</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>ARSEP (Association pour la Recherche sur la Sclerose en Plaques)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>JNLF (Journées de Neurologie de Langue Française)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Cognitive impairment is one of the symptoms of Multiple Sclerosis (MS), and it may occur&#xD;
      during the first years of the disease. It usually affects attention, information processing&#xD;
      speed and short term memory. To date, the mechanisms of this specific symptom remain unclear&#xD;
      (local or global inflammation, neurodegenerative processes).&#xD;
&#xD;
      Magnetic Resonance Imaging (MRI) can be useful to understand the pathophysiology of cognitive&#xD;
      impairment in MS. The investigators will combine conventional and non conventional MRI&#xD;
      sequences to determine the respective role of white matter and grey matter injury and the&#xD;
      cortical reorganization of neuronal networks.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Cognitive impairment in Multiple Sclerosis (MS) occurs in 50% of patients and has a major&#xD;
      social impact. There is no clear correlation between cognitive dysfunction and disease&#xD;
      duration and recent studies have pointed out that it may affects patients at the very early&#xD;
      stages of the disease especially in tasks involving sustained attention, processing speed,&#xD;
      working memory and executive function.&#xD;
&#xD;
      Recent imaging and pathology studies have shown that MS affects white matter as well as grey&#xD;
      matter. Unlike white matter lesion burden or distribution, grey matter atrophy has often been&#xD;
      linked to cognitive impairment. Microscopic injury of Normally Appearing White Matter (NAWM)&#xD;
      explored by non conventional MRI sequences has also been shown to be involved in&#xD;
      pathophysiology of cognitive disorders.&#xD;
&#xD;
      Nevertheless mechanisms of cognitive impairment remain unclear. The relationship between&#xD;
      cortical injury and diffuse white matter tracts damage and their respective contribution to&#xD;
      cognitive dysfunction affecting patients during the first years of the disease is still under&#xD;
      investigation.&#xD;
&#xD;
      This study aims at investigating structural and functional correlates of early cognitive&#xD;
      impairment using multimodal MRI.&#xD;
&#xD;
      Relapsing Remitting MS (RRMS) patients with disease duration of less than 5 years will be&#xD;
      included. Patients with and without cognitive impairment will be compared to healthy&#xD;
      controls. All subjects will perform a clinical and neuropsychological evaluation before the&#xD;
      MRI examination.&#xD;
&#xD;
      We will combine new available MRI techniques using a 3 Tesla magnet in order to evaluate&#xD;
      precisely cortical and white matter tracts lesions in patients with cognitive MS. These&#xD;
      techniques will include :&#xD;
&#xD;
        -  3D T1 sequences to study cortical atrophy using VBM.&#xD;
&#xD;
        -  Diffusion tensor imaging fibre tracking to study selected white matter tracts that may&#xD;
           be involved in cognitive disorders, such as the thalamus-cortical or the&#xD;
           striatum-cortical tracts connecting sub-cortical structures to the prefrontal cortex.&#xD;
&#xD;
        -  Functional MRI sequences during a working memory task and during the resting state in&#xD;
           order to describe functional networks and their possible reorganization in patients with&#xD;
           or without cognitive impairment.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2008</start_date>
  <completion_date type="Actual">December 2010</completion_date>
  <primary_completion_date type="Actual">December 2010</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">69</enrollment>
  <condition>Multiple Sclerosis</condition>
  <condition>Cognitive Impairment</condition>
  <arm_group>
    <arm_group_label>Relapsing Multiple Sclerosis patients</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>healthy volunteer</arm_group_label>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        -  Relapsing remitting Multiple Sclerosis patients&#xD;
&#xD;
          -  Age: 18-40 years&#xD;
&#xD;
          -  Evolving between 3 and 5 years&#xD;
&#xD;
          -  EDSS&lt;5&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Relapsing remitting Multiple Sclerosis patients&#xD;
&#xD;
          -  Age: 18-40 years&#xD;
&#xD;
          -  Evolving between 3 and 5 years&#xD;
&#xD;
          -  EDSS&lt;5&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  MRI exclusion criteria (metallic prothetic, pace maker etc)&#xD;
&#xD;
          -  Renal failure due to Gadolinium injection&#xD;
&#xD;
          -  Major depressive disorder&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bruno Stankoff, MD,PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Pitié-Salpêtrière Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pitie salpêtrière Hospital</name>
      <address>
        <city>PAris</city>
        <zip>75013</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>May 2010</verification_date>
  <study_first_submitted>July 6, 2010</study_first_submitted>
  <study_first_submitted_qc>July 6, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 7, 2010</study_first_posted>
  <last_update_submitted>July 30, 2012</last_update_submitted>
  <last_update_submitted_qc>July 30, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 31, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Multiple sclerosis</keyword>
  <keyword>Cognitive impairment</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Sclerosis</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
    <mesh_term>Cognitive Dysfunction</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

